EXAVIR THERAPEUTICS INC.

Omaha, NE · Biotech · Private

Ultra-long-acting nanoformulated injectable antiretroviral prodrug for HIV prevention and treatment

Claim this profile

Follows are private to you and power your alerts

Updated · exavirtherapeutics.com

Sector
Biotech
Headquarters
Omaha, NE
Total capital
$3M
Federal grants
$3M
3 awards · 2023–2025
Rank in peer group#229 of 514
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
9 pending

Capital timeline

202320242025FEDERAL ↑EQUITY ↓Cumulative $3M$1M$1M$1M
202320242025FEDERAL ↑EQUITY ↓Cumulative $3M$1M$1M$1M

Latest events

  • Federal grantHealth and Human S · Phase II · XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies$1M
  • Federal grantHealth and Human S · Phase II · XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies$1M
  • Federal grantHealth and Human S · Phase II · XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#229 · top 45%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 9
  • PendingLong-acting Formulations Of Heterocyclic GLP1 Receptor AgonistsUSPTOApplication PCTUS2025060685
  • PendingLong-acting Formulations Of Heterocyclic GLP1 Receptor AgonistsUSPTOApplication 63910381
  • PendingFormulations Of An Antiviral ProdrugUSPTOApplication 19165963
Show all 9 patent records
  • Long-acting Formulations Of Heterocyclic GLP1 Receptor AgonistsApplication PCTUS2025060685Pending
  • Long-acting Formulations Of Heterocyclic GLP1 Receptor AgonistsApplication 63910381Pending
  • Formulations Of An Antiviral ProdrugApplication 19165963Pending
  • Long-acting Formulations Of Heterocyclic GLP1 Receptor AgonistsApplication 63842217Pending
  • Long-acting Formulations Of Heterocyclic GLP1 Receptor AgonistsApplication 63736764Pending
  • Crystalline Forms Of An Antiviral ProdrugApplication PCTUS2024019702Pending
  • Formulations Of An Antiviral ProdrugApplication PCTUS2024019703Pending
  • Formulations Of An Antiviral ProdrugApplication 63491002Pending
  • Crystalline Forms Of An Antiviral ProdrugApplication 63490999Pending
  • Tremeau Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • Arbor Assets IncSimilar federal contract value in Biotech · null in contracts
  • Prothena Corp plcSimilar federal contract value in Biotech · null in contracts
  • Go Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • OPAL THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
  • GlycomineSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .